- Home
- HLVX vs ANIX Comparison
HLVX vs ANIX Comparison
Compare HLVX & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ANIX
- Stock Information
- Founded
- HLVX 2020
- ANIX 1982
- Country
- HLVX United States
- ANIX United States
- Employees
- HLVX N/A
- ANIX N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- ANIX Health Care
- Exchange
- HLVX Nasdaq
- ANIX Nasdaq
- Market Cap
- HLVX 104.3M
- ANIX 95.7M
- IPO Year
- HLVX 2022
- ANIX 1987
- Fundamental
- Price
- HLVX $2.09
- ANIX $3.37
- Analyst Decision
- HLVX Hold
- ANIX Strong Buy
- Analyst Count
- HLVX 1
- ANIX 3
- Target Price
- HLVX $2.00
- ANIX $9.00
- AVG Volume (30 Days)
- HLVX 862.9K
- ANIX 109.8K
- Earning Date
- HLVX 11-06-2025
- ANIX 09-10-2025
- Dividend Yield
- HLVX N/A
- ANIX N/A
- EPS Growth
- HLVX N/A
- ANIX N/A
- EPS
- HLVX N/A
- ANIX N/A
- Revenue
- HLVX N/A
- ANIX N/A
- Revenue This Year
- HLVX N/A
- ANIX N/A
- Revenue Next Year
- HLVX N/A
- ANIX N/A
- P/E Ratio
- HLVX N/A
- ANIX N/A
- Revenue Growth
- HLVX N/A
- ANIX N/A
- 52 Week Low
- HLVX $1.34
- ANIX $2.07
- 52 Week High
- HLVX $2.17
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- HLVX 51.29
- ANIX 60.27
- Support Level
- HLVX $2.07
- ANIX $3.31
- Resistance Level
- HLVX $2.11
- ANIX $3.09
- Average True Range (ATR)
- HLVX 0.02
- ANIX 0.16
- MACD
- HLVX -0.00
- ANIX 0.06
- Stochastic Oscillator
- HLVX 50.00
- ANIX 65.67
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.